Prediction of coronary no-reflow phenomenon in patients with ST-segment elevation myocardial infarction using macrophage migration inhibitory factor

Стендова доповідь №7
РОЗДІЛ: КАРДІОЛОГІЯ
МОДЕРАТОРИ : проф. Сичев Олег Сергійович, д.м.н. Іркін Олег Ігорович, д.м.н. Міщенко Лариса Анатоліївна

ДОПОВІДАЧ: I. Vyshnevska, TYE. Storozhenko, M. Kopytsya

4 коментарі до “Prediction of coronary no-reflow phenomenon in patients with ST-segment elevation myocardial infarction using macrophage migration inhibitory factor”

    1. The final study group was 90 patients, we tried to find the influence and correlation between no-reflow phenomenon and biomarker MIF (macrophage migration inhibitory factor). First of all we found that 41 patients had MBG 0-1 and 49 MBG 2-3. Then we analyzed ST-segment resolution (STR). The result was: only 16 patients from 41 had MBG 0-1 and STR < 70%, which characterized for no-reflow, and only 36 patients from 49 had prefect reperfusion with MBG 2-3 and STR>70%. Then we compared groups of patients with no-reflow and good reperfusion. Unfortunately, we made a mistake in presentation with number of patients.

    1. Patients received opioids and antithrombotic drugs, including fibrinolytics in rural areas with time to PCI more than 4-6 hours (but we excluded patients with facilitate PCI and included only primary PCI with bare-metal stent implantation), loading dose of statins, and life supportive therapy, oxygen, nitroglycerin e.c., if necessary.

      І.Р. Вишневська, Т.Є. Стороженко, М.П. Копиця

Залишити відповідь